Chromosomal/JJ
Microarray/NN
Testing/JJ
in/IN
42/CD
Korean/JJ
Patients/NNS
with/IN
Unexplained/JJ
Developmental/JJ
Delay/NNP
,/,
Intellectual/JJ
Disability/NN
,/,
Autism/NN
Spectrum/NN
Disorders/NNS
,/,
and/CC
Multiple/JJ
Congenital/JJ
Anomalies/NNS
./.
====================
Chromosomal/JJ
microarray/NN
(/(
CMA/NN
)/)
is/VBZ
a/DT
high-resolution/JJ
,/,
high-throughput/JJ
method/NN
of/IN
identifying/VBG
submicroscopic/JJ
genomic/JJ
copy/NN
number/NN
variations/NNS
(/(
CNVs/NNS
)/)
./.
====================
CMA/NN
has/VBZ
been/VBN
established/VBN
as/IN
the/DT
first-line/JJ
diagnostic/JJ
test/NN
for/IN
individuals/NNS
with/IN
developmental/JJ
delay/NN
(/(
DD/NN
)/)
,/,
intellectual/JJ
disability/NN
(/(
ID/NN
)/)
,/,
autism/NN
spectrum/NN
disorders/NNS
(/(
ASDs/NNS
)/)
,/,
and/CC
multiple/JJ
congenital/JJ
anomalies/NNS
(/(
MCAs/NNS
)/)
./.
====================
CMA/NN
analysis/NN
was/VBD
performed/VBN
in/IN
42/CD
Korean/JJ
patients/NNS
who/WP
had/VBD
been/VBN
diagnosed/VBN
with/IN
unexplained/JJ
DD/NN
,/,
ID/NN
,/,
ASDs/NNS
,/,
and/CC
MCAs/NNS
./.
====================
Clinically/RB
relevant/JJ
CNVs/NNS
were/VBD
discovered/VBN
in/IN
28/CD
patients/NNS
./.
====================
Variants/NNS
of/IN
unknown/JJ
significance/NN
were/VBD
detected/VBN
in/IN
13/CD
patients/NNS
./.
====================
The/DT
diagnostic/JJ
yield/VB
was/VBD
high/JJ
(/(
66.7/CD
%/NN
)/)
./.
====================
CMA/NN
is/VBZ
a/DT
superior/JJ
diagnostic/JJ
tool/NN
compared/VBN
with/IN
conventional/JJ
karyotyping/VBG
and/CC
fluorescent/JJ
in/FW
situ/FW
hybridization/NN
./.
====================
Chromosomal/JJ
microarray/NN
(/(
CMA/NN
)/)
analysis/NN
is/VBZ
widely/RB
recognized/VBN
and/CC
recommended/VBD
as/IN
the/DT
first-tier/JJ
cytogenetic/JJ
diagnostic/JJ
test/NN
for/IN
patients/NNS
with/IN
developmental/JJ
delay/VBP
(/(
DD/NN
)/)
,/,
intellectual/JJ
disability/NN
(/(
ID/NN
)/)
,/,
autism/NN
spectrum/NN
disorders/NNS
(/(
ASDs/NNS
)/)
,/,
or/CC
multiple/JJ
congenital/JJ
anomalies/NNS
(/(
MCAs/NNS
)/)
[/(
1/CD
,/,
2/CD
]/)
./.
====================
DD/NN
describes/VBZ
persons/NNS
aged/JJ
5/CD
years/NNS
or/CC
younger/JJR
who/WP
have/VBP
demonstrated/VBN
several/JJ
significant/JJ
delays/NNS
in/IN
the/DT
following/VBG
areas/NNS
:/:
cognitive/JJ
,/,
speech/JJ
,/,
social/personal/JJ
,/,
fine/gross/RB
motor/NN
,/,
and/CC
daily/RB
activities/NNS
./.
====================
ID/NN
is/VBZ
diagnosed/VBN
at/IN
or/CC
after/IN
age/NN
5/CD
years/NNS
when/WRB
one/CD
’/NN
s/NNS
intelligence/NN
quotient/JJ
is/VBZ
deemed/VBN
to/TO
be/VB
less/RBR
than/IN
70/CD
and/CC
when/WRB
permanent/JJ
intellectual/JJ
impairment/JJ
results/NNS
in/IN
a/DT
general/JJ
deficit/NN
in/IN
adaptive/JJ
behaviors/NNS
[/(
3/CD
]/)
./.
====================
ASD/NN
comprises/VBZ
a/DT
wide/JJ
range/NN
of/IN
neurological/JJ
and/CC
developmental/JJ
disabilities/NNS
,/,
encompassing/VBG
autism/NN
,/,
Asperger/NN
syndrome/NN
,/,
pervasive/JJ
developmental/JJ
disorders/NNS
,/,
and/CC
childhood/NN
disintegrative/JJ
disorder/NN
[/(
3/CD
]/)
./.
====================
MCAs/NNS
refer/VBP
to/TO
the/DT
presence/NN
of/IN
multiple/JJ
major/JJ
malformations/NNS
,/,
such/JJ
as/IN
cardiac/JJ
defects/NNS
and/CC
missing/VBG
limbs/NNS
,/,
or/CC
3/CD
or/CC
more/RBR
minor/JJ
malformations/NNS
(/(
e.g./FW
,/,
syndactyly/RB
and/CC
club/NN
feet/NN
)/)
./.
====================
Combined/JJ
,/,
these/DT
disorders/NNS
are/VBP
highly/RB
prevalent/JJ
(/(
DD/ID/NN
,/,
up/IN
to/TO
3/CD
%/NN
[/(
4/CD
]/)
;/:
ASDs/NNS
,/,
1/CD
%/NN
to/TO
2/CD
%/NN
[/(
5/CD
]/)
;/:
MCAs/NNP
,/,
0.16/CD
%/NN
[/(
6/CD
]/)
)/)
and/CC
might/MD
have/VBP
a/DT
genetic/JJ
etiology/NN
,/,
such/JJ
as/IN
copy/RB
number/NN
variation/NN
(/(
CNV/NN
)/)
and/CC
loss/NN
of/IN
heterozygosity/NN
(/(
LOH/NN
)/)
./.
====================
The/DT
prevalence/NN
of/IN
pathogenic/JJ
CNVs/NNS
is/VBZ
high/JJ
in/IN
those/DT
with/IN
autism/NN
(/(
5/CD
%/NN
to/TO
10/CD
%/NN
)/)
and/CC
children/NN
with/IN
both/DT
ID/NN
and/CC
MCAs/NNS
(/(
20/CD
%/NN
to/TO
25/CD
%/NN
)/)
[/(
7/CD
]/)
./.
====================
CMA/NN
is/VBZ
a/DT
high-resolution/JJ
,/,
high-throughput/JJ
technique/NN
that/DT
detects/VBZ
submicroscopic/JJ
CNVs/NNS
that/DT
are/VBP
not/RB
observable/JJ
with/IN
traditional/JJ
cytogenetic/JJ
analysis/NN
tools/NNS
,/,
including/VBG
karyotyping/VBG
and/CC
fluorescence/NN
in/FW
situ/FW
hybridization/NN
(/(
FISH/NN
)/)
[/(
8/CD
]/)
./.
====================
Further/RB
,/,
CMA/NN
has/VBZ
a/DT
higher/JJR
diagnostic/JJ
yield/VB
(/(
12.2/CD
%/NN
on/IN
average/NN
)/)
than/IN
conventional/JJ
tests/NNS
[/(
1/CD
,/,
2/CD
]/)
./.
====================
However/RB
,/,
as/IN
with/IN
next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
,/,
interpreting/VBG
microarray/NN
anomalies/NNS
poses/VBZ
challenges/NNS
for/IN
clinical/JJ
laboratories/NNS
and/CC
clinicians/NNS
in/IN
establishing/VBG
the/DT
clinical/JJ
significance/NN
and/CC
pathogenicity/NN
of/IN
the/DT
detected/VBN
CNVs/NNS
./.
====================
Variability/NN
in/IN
the/DT
interpretation/NN
arises/VBZ
from/IN
internal/JJ
databases/NNS
that/DT
are/VBP
limited/JJ
by/IN
the/DT
number/NN
of/IN
cases/NNS
that/WDT
are/VBP
analyzed/VBN
;/:
racial/JJ
and/CC
socio-economic/JJ
bias/NNS
;/:
and/CC
the/DT
complete/JJ
lack/NN
of/IN
openly/RB
accessible/JJ
centralized/JJ
resources/VBZ
for/IN
sharing/VBG
CMA/NN
data/NNS
,/,
patient/NN
phenotypes/NNS
,/,
and/CC
clinical/JJ
interpretations/NNS
between/IN
laboratories/NNS
in/IN
South/NN
Korea/NN
and/CC
overseas/IN
./.
====================
Moreover/RB
,/,
disparate/JJ
technology/NN
platforms/NNS
with/IN
varying/VBG
array/NN
designs/NNS
,/,
resolution/NN
,/,
and/CC
coverage/VBP
render/VBP
the/DT
standardization/NN
of/IN
CMA/NN
and/CC
its/PRP$
uniform/JJ
interpretation/NN
more/RBR
difficult/JJ
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
attempted/VBD
to/TO
establish/VB
the/DT
origin/NN
of/IN
DD/NN
,/,
ID/NN
,/,
ASDs/NNS
,/,
and/CC
MCAs/NNS
in/IN
42/CD
Korean/JJ
patients/NNS
;/:
demonstrate/VBP
the/DT
value/NN
of/IN
CMA/NN
in/IN
determining/VBG
the/DT
genomic/JJ
etiology/NN
of/IN
unexplained/JJ
DD/NN
,/,
ID/NN
,/,
and/CC
MCAs/NNS
;/:
and/CC
discuss/VBP
the/DT
challenges/NNS
facing/VBG
CMA/NN
./.
====================
Patients/NNS
====================
The/DT
parents/NNS
and/CC
guardians/NNS
of/IN
the/DT
probands/NNS
were/VBD
informed/VBN
about/RB
the/DT
microarray/NN
study/NN
and/CC
given/VBN
information/NN
about/IN
the/DT
risks/NNS
,/,
benefits/VBZ
,/,
and/CC
limitations/NNS
of/IN
CMA/NN
testing/NN
./.
====================
Informed/VBN
consent/NN
was/VBD
obtained/VBN
by/IN
a/DT
clinical/JJ
geneticist/NN
or/CC
the/DT
researchers/NNS
./.
====================
The/DT
study/NN
sample/NN
comprised/VBD
42/CD
individuals/NNS
(/(
29/CD
males/NNS
,/,
13/CD
females/NNS
)/)
,/,
ranging/VBG
in/IN
age/NN
from/IN
newborns/NNS
to/TO
38/CD
years/NNS
,/,
who/WP
had/VBD
negative/JJ
test/NN
results/VBZ
for/IN
metabolic/JJ
disorders/NNS
and/CC
other/JJ
suspected/JJ
disorders/NNS
and/CC
did/VBD
not/RB
present/JJ
with/IN
any/DT
recognizable/JJ
syndrome/NN
./.
====================
Clinical/JJ
data/NNS
,/,
including/VBG
medical/JJ
history/JJ
,/,
were/VBD
collected/VBN
from/IN
the/DT
medical/JJ
records/NNS
and/CC
the/DT
parents/NNS
and/CC
guardians/NNS
of/IN
the/DT
probands/NNS
./.
====================
General/JJ
observations/NNS
for/IN
dysmorphic/JJ
features/NNS
were/VBD
made/VBN
,/,
and/CC
the/DT
height/NN
and/CC
head/NN
circumference/NN
were/VBD
measured/VBN
by/IN
the/DT
clinician/JJ
or/CC
the/DT
researchers/NNS
./.
====================
DNA/NN
preparation/NN
====================
Blood/NN
samples/NNS
were/VBD
collected/VBN
at/IN
the/DT
time/NN
of/IN
consent/JJ
./.
====================
Genomic/JJ
DNA/NN
was/VBD
extracted/VBN
from/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
using/VBG
the/DT
AccuPure/NN
Cell/Blood/NN
DNA/NN
Mini/NN
Kit/NN
(/(
AccuBioMed/JJ
Co/NN
,/,
Ltd/JJ
,/,
New/NN
Taipei/NNS
City/NN
,/,
Taiwan/NNP
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
./.
====================
DNA/NN
concentration/NN
and/CC
quality/NN
were/VBD
measured/VBN
using/VBG
a/DT
NanoDrop/JJ
One/CD
Microvolume/NN
UV-Vis/NN
spectrophotometer/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
,/,
Waltham/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
and/CC
a/DT
Fragment/JJ
Analyzer/NN
(/(
Advanced/JJ
Analytical/JJ
Technologies/NNS
,/,
Ankeny/DT
,/,
IA/NN
,/,
USA/NNP
)/)
./.
====================
Chromosomal/JJ
microarray/NN
====================
CMA/NN
tests/NNS
were/VBD
performed/VBN
with/IN
Affymetrix/JJ
CytoScan/NN
750K/NN
arrays/NNS
(/(
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
a/DT
GeneChip/NN
GCS3000dx/NN
V2/NN
scanner/NN
(/(
Affymetrix/JJ
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
./.
====================
The/DT
array/NN
had/VBD
750,436/CD
markers/NNS
(/(
550,000/CD
non-polymorphic/JJ
markers/NNS
and/CC
200,436/CD
single/JJ
nucleotide/NN
polymorphism/NN
markers/NNS
)/)
,/,
based/VBN
on/IN
genome/NN
build/JJ
hg19/NN
./.
====================
The/DT
results/NNS
were/VBD
analyzed/VBN
with/IN
Chromosome/NN
Analysis/NN
Suite/NN
ver/RB
./.
====================
3.2.0.1252/CD
(/(
Affymetrix/JJ
)/)
./.
====================
Interpretation/NN
====================
CNVs/NNS
were/VBD
categorized/VBN
as/IN
pathogenic/JJ
,/,
benign/JJ
,/,
and/CC
variants/NNS
of/IN
uncertain/JJ
significance/NN
(/(
VUS/NNS
)/)
by/IN
considering/VBG
gene/NN
content/NN
,/,
size/NN
,/,
inheritance/VBP
pattern/NN
,/,
and/CC
previously/RB
reported/VBD
microdeletion/NN
or/CC
microduplication/NN
regions/NNS
./.
====================
University/NN
of/IN
California/NN
Santa/NN
Cruz/NN
Genome/NN
Browser/NN
was/VBD
employed/VBN
to/TO
check/VB
all/DT
of/IN
the/DT
information/NN
relevant/JJ
to/TO
the/DT
locations/NNS
of/IN
the/DT
CNVs/NNS
./.
====================
dbVar/RB
(/(
https/NNS
:/:
//www.ncbi.nlm.nih.gov/dbvar/JJ
)/)
and/CC
the/DT
Database/NN
of/IN
Chromosomal/JJ
Imbalance/NN
and/CC
Phenotype/JJ
in/IN
Humans/JJ
using/VBG
Ensembl/JJ
Resources/NNS
(/(
https/NNS
:/:
//decipher.sanger.ac.uk//JJ
)/)
were/VBD
consulted/VBN
to/TO
check/VB
clinically/RB
relevant/JJ
structural/JJ
variations/NNS
and/CC
determine/VBP
whether/IN
the/DT
observed/VBN
CNVs/NNS
were/VBD
of/IN
clinical/JJ
significance/NN
./.
====================
We/PRP
considered/VBD
CNVs/NNS
to/TO
be/VB
causative/JJ
if/IN
the/DT
variant/JJ
was/VBD
responsible/JJ
for/IN
a/DT
known/JJ
syndrome/NN
;/:
encompassed/VBN
a/DT
gene/NN
(/(
s/NNS
)/)
of/IN
known/JJ
function/NN
;/:
or/CC
occurred/VBD
de/FW
novo/FW
or/CC
,/,
if/IN
inherited/VBN
,/,
the/DT
parent/JJ
was/VBD
variably/RB
affected/VBN
or/CC
if/IN
the/DT
involved/VBN
gene/NN
(/(
s/NNS
)/)
had/VBD
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
ID/DD/ASDs/NNS
in/IN
public/JJ
databases/NNS
and/CC
the/DT
scientific/JJ
literature/NN
./.
====================
The/DT
term/NN
VUS/NN
was/VBD
used/VBN
if/IN
the/DT
variants/NNS
affected/VBD
a/DT
gene/NN
(/(
s/NNS
)/)
of/IN
unknown/JJ
clinical/JJ
significance/NN
and/CC
if/IN
,/,
at/IN
same/JJ
time/NN
,/,
the/DT
size/NN
was/VBD
substantially/RB
less/RBR
than/IN
100/CD
kb/NN
(/(
the/DT
average/JJ
resolution/NN
of/IN
the/DT
probes/NNS
used/VBN
)/)
and/CC
when/WRB
the/DT
family/NN
studies/NNS
were/VBD
inconclusive/JJ
or/CC
unavailable/JJ
[/(
9/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
41/CD
clinically/RB
relevant/JJ
CNVs/NNS
were/VBD
detected/VBN
in/IN
28/CD
(/(
66.7/CD
%/NN
)/)
patients/NNS
:/:
three/CD
(/(
10.7/CD
%/NN
)/)
of/IN
those/DT
presenting/VBG
with/IN
MCAs/NNS
,/,
23/CD
(/(
82.1/CD
%/NN
)/)
with/IN
a/DT
variable/JJ
degree/NN
of/IN
DD/NN
or/CC
ID/NN
,/,
and/CC
two/CD
(/(
7.1/CD
%/NN
)/)
with/IN
varying/VBG
degrees/NNS
of/IN
ID/NN
and/CC
ASDs/NNS
;/:
10/CD
(/(
35.7/CD
%/NN
)/)
patients/NNS
had/VBD
multiple/JJ
rearrangements/NNS
./.
====================
Among/IN
28/CD
pathogenic/JJ
cases/NNS
,/,
nine/CD
were/VBD
diagnosed/VBN
with/IN
microdeletion/microduplication/NN
syndromes/NNS
,/,
including/VBG
1p36/NN
deletion/NN
syndrome/NN
,/,
5q14.3/CD
deletion/NN
syndrome/NN
,/,
16p11.2/CD
deletion/NN
syndrome/NN
,/,
16p11.2/CD
duplication/NN
syndrome/NN
,/,
19p/JJ
duplication/NN
syndrome/NN
,/,
9p/JJ
duplication/NN
syndrome/NN
,/,
19p13.2/CD
deletion/NN
syndrome/NN
,/,
and/CC
22q11.2/CD
duplication/NN
syndrome/NN
./.
====================
In/IN
this/DT
study/NN
,/,
more/RBR
pathogenic/JJ
duplications/NNS
were/VBD
observed/VBN
than/IN
deletions/NNS
(/(
22/CD
vs./CC
19/CD
)/)
./.
====================
Also/RB
,/,
12/CD
cases/NNS
(/(
28.6/CD
%/NN
)/)
were/VBD
VUS/NN
,/,
and/CC
two/CD
cases/NNS
(/(
4.8/CD
%/NN
)/)
were/VBD
benign/JJ
CNVs/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
Genomic/JJ
CNVs/NNS
can/MD
contribute/VB
to/TO
the/DT
etiologies/NNS
of/IN
DD/NN
,/,
ID/NN
,/,
ASDs/NNS
,/,
and/CC
MCAs/NNS
./.
====================
With/IN
its/PRP$
proven/JJ
diagnostic/JJ
yield/VB
,/,
CMA/NN
has/VBZ
been/VBN
recommended/VBN
by/IN
a/DT
number/NN
of/IN
professional/JJ
societies/NNS
as/IN
part/NN
of/IN
the/DT
standard/JJ
assessment/NN
for/IN
individuals/NNS
in/IN
whom/WP
the/DT
underlying/VBG
cause/VBP
is/VBZ
unclear/JJ
[/(
10/CD
,/,
11/CD
]/)
./.
====================
Evaluating/VBG
genomic/JJ
variants/NNS
identified/VBD
by/IN
CMA/NN
is/VBZ
time-consuming/JJ
and/CC
difficult/JJ
./.
====================
Variations/NNS
in/IN
their/PRP$
interpretat/JJ
ion/NN
are/VBP
not/RB
uncommon/JJ
due/JJ
to/TO
platform/VB
differences/NNS
(/(
e.g./FW
,/,
resolution/NN
and/CC
array/NN
design/NN
)/)
,/,
lack/VBP
of/IN
standardization/NN
,/,
and/CC
differences/NNS
in/IN
the/DT
resources/NNS
that/DT
are/VBP
available/JJ
to/TO
and/CC
the/DT
expertise/JJ
of/IN
the/DT
bioinformatics/NNS
team/JJ
and/CC
clinicians/NNS
[/(
12/CD
]/)
./.
====================
At/IN
the/DT
time/NN
of/IN
writing/VBG
,/,
South/NN
Korea/NN
’/CD
s/NNS
National/JJ
Health/NN
Insurance/NN
(/(
NHI/NN
)/)
does/VBZ
not/RB
recognize/VB
CMA/NN
as/IN
a/DT
medically/RB
necessary/JJ
test/NN
nor/CC
does/VBZ
it/PRP
subsidize/VBP
the/DT
cost/JJ
of/IN
CMA/NN
testing/VBG
./.
====================
NHI/DT
allows/VBZ
only/RB
multiplex/JJ
ligation-dependent/JJ
probe/NN
amplification/NN
tests/NNS
for/IN
four/CD
microdeletion/NN
syndromes/NNS
:/:
Angelman/Prader-Willi/NN
syndrome/NN
,/,
DiGeorge/JJ
syndrome/NN
,/,
Miller-Dieker/NN
syndrome/NN
,/,
and/CC
Williams/NNS
syndrome/NN
[/(
13/CD
]/)
./.
====================
Although/IN
subsidies/NNS
for/IN
NGS/NN
genetic/JJ
testing/NN
have/VBP
received/VBN
government/JJ
approval/JJ
this/DT
year/NN
,/,
NGS/NN
tests/NNS
are/VBP
limited/JJ
to/TO
a/DT
small/JJ
number/NN
of/IN
pre-approved/JJ
diagnostic/JJ
gene/NN
panels/NNS
./.
====================
With/IN
NGS/NN
in/IN
the/DT
early/JJ
stages/NNS
of/IN
clinical/JJ
application/NN
in/IN
this/DT
country/NN
due/JJ
to/TO
government/JJ
restrictions/NNS
and/CC
due/JJ
to/TO
insufficient/JJ
human/JJ
bioinformatics/NNS
resources/VBZ
and/CC
lack/VBP
of/IN
a/DT
central/JJ
system/NN
for/IN
a/DT
nationwide/JJ
interlaboratory/JJ
QA/NN
program/NN
and/CC
data/NNS
sharing/VBG
,/,
there/EX
is/VBZ
currently/RB
no/DT
affordable/JJ
high-resolution/JJ
,/,
high-throughput/JJ
diagnostic/JJ
genetic/JJ
test/NN
for/IN
CNVs/NNS
available/JJ
to/TO
the/DT
public/JJ
in/IN
South/NN
Korea/NN
./.
====================
One/CD
major/JJ
limitation/NN
of/IN
this/DT
study/NN
is/VBZ
that/DT
due/JJ
to/TO
the/DT
costs/NNS
of/IN
CMA/NN
,/,
we/PRP
were/VBD
unable/JJ
to/TO
investigate/VB
the/DT
families/NNS
of/IN
the/DT
probands/NNS
to/TO
confirm/VB
the/DT
clinical/JJ
significance/NN
of/IN
some/DT
detected/VBN
CNVs/NNS
./.
====================
Other/JJ
limitations/NNS
were/VBD
associated/VBN
with/IN
the/DT
sensitivity/NN
and/CC
specificity/NN
of/IN
the/DT
chosen/NN
CMA/NN
testing/NN
platform/NN
;/:
low-level/JJ
mosaicism/NN
and/CC
balanced/JJ
rearrangements/NNS
might/MD
not/RB
be/VB
detected/VBN
[/(
14/CD
]/)
./.
====================
For/IN
example/NN
,/,
in/IN
patient/NN
26/CD
,/,
FISH/NN
revealed/VBD
a/DT
derivative/JJ
chromosome/NN
15/CD
resulting/VBG
from/IN
a/DT
translocation/NN
between/IN
chromosomes/NNS
9/CD
and/CC
15/CD
./.
====================
This/DT
study/NN
illustrates/VBZ
the/DT
ability/NN
of/IN
CMA/NN
to/TO
greatly/RB
improve/VBP
the/DT
diagnostic/JJ
yield/VB
(/(
66.7/CD
%/NN
)/)
for/IN
patients/NNS
with/IN
unexplained/JJ
DD/NN
,/,
ID/NN
,/,
ASDs/NNS
,/,
and/CC
MCAs/NNS
./.
====================
However/RB
,/,
it/PRP
is/VBZ
also/RB
important/JJ
to/TO
note/VB
that/IN
the/DT
clinical/JJ
impact/NN
of/IN
CMA/NN
beyond/JJ
the/DT
diagnosis/NN
is/VBZ
very/RB
limited/JJ
./.
====================
It/PRP
is/VBZ
unlikely/JJ
that/IN
any/DT
genomic/JJ
genetic/JJ
test/NN
will/MD
lead/VB
to/TO
better/RBR
clinical/JJ
outcomes/NNS
for/IN
adults/NNS
with/IN
DD/NN
,/,
ID/NN
,/,
ASDs/NNS
,/,
and/CC
MCAs/NNS
,/,
because/IN
the/DT
genetic/JJ
diagnosis/NN
often/RB
does/VBZ
not/RB
lead/VB
to/TO
an/DT
intervention/NN
strategy/NN
for/IN
adult/JJ
patients/NNS
./.
====================
Nevertheless/RB
,/,
the/DT
diagnosis/NN
will/MD
influence/VB
the/DT
parents/NNS
’/CD
reproductive/JJ
planning/VBG
,/,
assist/VBP
genetic/JJ
counselors/NNS
in/IN
assessing/VBG
recurrence/NN
risks/NNS
and/CC
providing/VBG
guidance/NN
to/TO
the/DT
patients/NNS
’/CD
families/NNS
,/,
and/CC
ultimately/RB
help/VBP
reduce/VBP
childhood/NN
morbidity/NN
and/CC
mortality/NN
./.
====================
Therefore/RB
,/,
we/PRP
recommend/VBP
the/DT
introduction/NN
and/CC
recognition/NN
of/IN
CMA/NN
as/IN
the/DT
first-tier/JJ
diagnostic/JJ
genetic/JJ
test/NN
in/IN
South/NN
Korea/NN
./.
====================
Chromosomal/JJ
microarray/NN
results/VBZ
====================
